Literature DB >> 2996409

The acquired immunodeficiency syndrome in infants and children.

A J Ammann.   

Abstract

The classification of the pediatric acquired immunodeficiency syndrome (AIDS) is based on epidemiologic, immunologic, and virologic data. Persons at risk include mothers who use intravenous drugs, infants who have received blood transfusions from subjects with risk factors, patients receiving factor VIII therapy, and infants born to heterosexual mothers with bisexual husbands. A distinct immunologic phenotype, rarely seen in other immunodeficiency disorders, is associated with pediatric AIDS consisting of polyclonal hypergammaglobulinemia and T-cell immunodeficiency. Detection of antibody to the AIDS retrovirus or isolation of virus are essential in establishing a diagnosis. During early infancy, viral isolation is essential as passive transfer of material IgG may occur. Primary immunodeficiency diseases, in particular adenosine deaminase and purine nucleoside phosphorylase deficiency, should be excluded. A diagnosis of pediatric AIDS may be established in a patient who has a risk factor associated with AIDS, polyclonal hypergammaglobulinemia, T-cell immunodeficiency, and antibody to the AIDS retrovirus or isolation of virus.

Entities:  

Keywords:  Acquired Immunodeficiency Syndrome; Age Factors; Americas; Antibodies; Biology; Demographic Factors; Developed Countries; Developing Countries; Diseases; Hematological Effects; Hemic System; Hiv Infections; Immunity; Immunoglobulin Alterations; Immunologic Factors; Immunological Effects; Infant; North America; Northern America; Physiology; Population; Population At Risk; Population Characteristics; United States; Viral Diseases; Youth

Mesh:

Substances:

Year:  1985        PMID: 2996409     DOI: 10.7326/0003-4819-103-5-734

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  7 in total

1.  Pediatrics: AIDS in children.

Authors:  A Ammann
Journal:  West J Med       Date:  1986-08

2.  Intravenous immunoglobulin in HIV infection: evidence for the efficacy of treatment.

Authors:  R A Hague; P L Yap; J Y Mok; O B Eden; N A Coutts; J G Watson; F D Hargreaves; J M Whitelaw
Journal:  Arch Dis Child       Date:  1989-08       Impact factor: 3.791

3.  Hyperviscosity in HIV infected children--a potential hazard during intravenous immunoglobulin therapy.

Authors:  R A Hague; O B Eden; P L Yap; J Y Mok; P Rae
Journal:  Blut       Date:  1990 Aug-Sep

4.  Oral manifestations of human immunodeficiency virus infection.

Authors:  J B Epstein; R G Mathias
Journal:  Can Fam Physician       Date:  1988-08       Impact factor: 3.275

5.  Transmission of human immunodeficiency virus from parents to only one dizygotic twin.

Authors:  C L Park; H Streicher; R Rothberg
Journal:  J Clin Microbiol       Date:  1987-06       Impact factor: 5.948

6.  Human immunodeficiency virus infection in multi-transfused patients with thalassaemia major.

Authors:  P E Manconi; C Dessí; G Sanna; F Argiolu; P Pellegrini-Bettoli; R Piro; O Masotti; A Cao
Journal:  Eur J Pediatr       Date:  1988-04       Impact factor: 3.183

7.  Human immunodeficiency virus contains an epitope immunoreactive with thymosin alpha 1 and the 30-amino acid synthetic p17 group-specific antigen peptide HGP-30.

Authors:  P H Naylor; C W Naylor; M Badamchian; S Wada; A L Goldstein; S S Wang; D K Sun; A H Thornton; P S Sarin
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.